Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management
Top Cited Papers
- 1 March 2003
- journal article
- review article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 3 (3), 148-155
- https://doi.org/10.1016/s1473-3099(03)00545-0
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitisAnnals Of The Rheumatic Diseases, 2002
- Local Role for Tumor Necrosis Factor Alpha in the Pulmonary Inflammatory Response toMycobacterium tuberculosisInfectionInfection and Immunity, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Restraining mycobacteria: Role of granulomas in mycobacterial infectionsImmunology & Cell Biology, 2000
- The role of cytokines in the immune response to tuberculosisResearch in Immunology, 1996
- Assessment of a Possible Imbalance between Tumor Necrosis Factor (TNF) and Soluble TNF Receptor Forms in Tuberculous Infection of the Central Nervous SystemThe Journal of Infectious Diseases, 1995
- Tumor necrosis factor-α is required in the protective immune response against mycobacterium tuberculosis in miceImmunity, 1995
- Construction and initial characterization of a mouse-human chimeric anti-TNF antibodyMolecular Immunology, 1993
- The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infectionCell, 1989
- Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation.The Journal of Experimental Medicine, 1988